Lucy Therapeutics
CEO: Amy Ripka
Lucy Therapeutics is leading a new approach to treating Rett Syndrome (RTT). RTT is a devastating pediatric disease, for which there are no drug treatments currently available. Children (primarily girls) with RTT require care 24 hours a day, 7 days a week due to debilitating conditions, including seizures, anxiety, lack of speech and sleep disorders, as well as cardiac and muscular issues. Lucy Therapeutics aims to provide treatment options that work to restrict the impact of the disease at the source rather than committing treatment resources exclusively to ameliorating symptoms. Their innovative approach has the potential to also provide new options for treating similar neurologically-focused diseases, including Parkinson's Disease (PD) and Alzheimer's Disease (AD).